Drug Shortages in Spain Have Reached Critical Levels, Affecting Over 1,500 Medications

Drug shortages in Spain have reached critical levels, with over 11,785 reported incidents involving 1,538 medications, according to LUDA Partners, a leading pharmaceutical data provider. The issue has persisted for years, with specific drugs like Tromalyt and Jorveza facing persistent supply gaps, according to Juanjo Molina, president of the College of Pharmacists of Cuenca.

Understanding the Scope of Drug Shortages in Spain

Recent data from LUDA Partners, which tracks shortages across 3,700 affiliated pharmacies, reveals a significant rise in medication unavailability. The organization reported 11,785 incidents in the past weeks, involving 1,538 distinct pharmaceutical products. This highlights a systemic challenge affecting both patients and healthcare providers.

The Spanish Agency of Medicines and Health Products (AEMPS) also acknowledges the issue, though it has not provided updated statistics beyond the 2023 report. Industry experts attribute the shortages to a mix of supply chain disruptions and economic pressures.

Key Medications Affected and Their Impact

Several critical medications have been highlighted in the shortage reports. Tromalyt, a medication containing acetylsalicylic acid (the active ingredient in aspirin), is among the most affected. The 75-milligram formulation, packaged in 30 tablets, has been in short supply for years, according to Molina. A 100-milligram variant from another manufacturer and Aspirin Plus 500 mg/50 mg are also affected.

In Castilla-La Mancha, five medications are most frequently reported as unavailable: Fixaprost (used for glaucoma), Amchafibrin (for hemorrhage prevention), Kreon (for pancreatic insufficiency), Zaditen (an antihistamine for allergies), and Jorveza (for eosinophilic esophagitis). Molina noted that while some shortages are temporary, others persist due to limited generic alternatives.

Why Are Certain Medications Like Tromalyt Experiencing Shortages?

LUDA Partners cites multiple factors contributing to the shortages. These include seasonal demand spikes, rising production costs, global supply chain tensions, and social media-driven demand surges. Structural issues, such as low profit margins for certain medications, also play a role, according to industry analyses.

Spain’s pharmaceutical sector faces unique challenges. While other European countries report similar issues, Spain’s advanced tracking system—LUDA’s real-time medication availability tool—provides a competitive edge in identifying and mitigating shortages.

What Can Patients and Healthcare Providers Do?

When shortages occur, pharmacists and physicians often seek alternatives. For example, Jorveza’s 0.5-milligram dose can replace the unavailable 1-milligram variant, though this requires physician approval. Molina emphasized that while shortages are concerning, they are not widespread, and substitutions are typically available.

Patients are advised to communicate with their healthcare providers promptly. The AEMPS recommends checking the official website for updates on medication availability and exploring generic alternatives when possible.

How Does Spain Compare to Other European Nations?

Drug shortages are not unique to Spain. Countries like Germany and France have also reported similar issues, though the scale varies. Spain’s LUDA system, which maps real-time medication availability, is considered a model for proactive management. However, experts note that global supply chain instability remains a shared challenge.

According to a 2023 European Medicines Agency report, 12% of EU member states experienced critical drug shortages in 2022, with Spain ranking in the mid-range for severity.

What’s Next for Spain’s Pharmaceutical Supply Chain?

Industry leaders are calling for policy reforms to address long-term sustainability. These include revising pricing structures to ensure profitability for essential medications and investing in domestic production. The Spanish government has yet to announce specific measures, but the AEMPS has pledged to monitor the situation closely.

As the healthcare sector adapts, transparency and collaboration between manufacturers, regulators, and pharmacies will be critical. For now, patients are urged to stay informed and work closely with their doctors to navigate supply challenges.